| |
Combining the industry-leading GPEx®️ cell line development with streamlined drug substance manufacturing.
|
|
Today’s Big NewsDec 19, 2024 |
|
Just secured round from NVIDIA & Accel, Nebius is revolutionizing Life Sciences and Healthcare with powerful GPU Cloud. Cutting-edge AI/ML solutions, competitive pricing, and expert architectural support for breakthrough research. Learn more.
|
|
| By Nick Paul Taylor Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 million upfront for global rights to two preclinical antibodies. |
|
|
|
By Nick Paul Taylor Days after UCB reported the failure of its Novartis-partnered program, Roche has shared details of its own alpha-synuclein flop while clinging onto signs of clinical benefit that could still save the candidate. |
By James Waldron Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million upfront to help bypass the blood-brain barrier. |
Sponsored by Inventus Discover how the Inventus Connect eSIM solutions, designed specifically for provisioned devices in clinical trials, are contributing to better patient outcomes with the only seamless global connectivity solution for eCOA. |
By Nick Paul Taylor Vertex has reported a phase 2 win that dented confidence in its pain prospect suzetrigine. The trial linked the near-approval molecule to a significant improvement from baseline, but placebo performed similarly, triggering a 12% drop in Vertex’s share price in premarket trading. |
Sponsored by NVIDIA Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a reality in clinical development pipelines. |
By James Waldron KdT Ventures has signed off on a $608 million biobucks deal for NGM Biopharmaceuticals' phase 2-ready metabolic-dysfunction associated steatohepatitis drug, with the VC firm setting up a new company to house the therapy. |
By James Waldron A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, setting the company up to begin a “broad” phase 3 program next year. |
By Darren Incorvaia After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with a resubmission or appeal. But a new lawsuit, filed on Dec. 17 in the Southern District of New York, alleges that the company was overly optimistic in its statements leading up to the rejection. |
By Gabrielle Masson Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a new data analysis that found the investigational treatment improved overall survival by 68% for patients with a rare, life-threatening complication of a bone marrow transplant. |
By James Waldron Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured $140 million in series A funds to push forward its potential Keytruda contender. |
By Darren Incorvaia Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just under 50%, a company spokesperson confirmed to Fierce Biotech. |
By Gabrielle Masson Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. |
By Gabrielle Masson Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas including drug discovery, chemistry and medical devices. |
By Fraiser Kansteiner Novartis confirmed Thursday that it’s closing down MorphoSys sites in Munich and Boston in a move that’s expected to result in around 330 layoffs. The company made the decision in November as it looks to “integrate all portfolio activities into Novartis." |
By Noah Tong,Emma Beavins Congress reached a deal to fund the government through March 14 on Tuesday night. By Wednesday, Trump and his advisors said no. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
|
|---|
|
|
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
